William J. Rifkin, Rami S. Kantar, MD, Safi Ali-Khan, Natalie M. Plana, J. Rodrigo Diaz-Siso, MD, Manos Tsakiris, PhD, MSc, and Eduardo D. Rodriguez, MD, DDS
Facial transplantation provides a viable option for those patients with severe facial defects who are more likely to adapt to their new facial appearance.
AMA J Ethics. 2018;20(4):309-323. doi:
10.1001/journalofethics.2018.20.4.peer1-1804.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.